Clinical Trial

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of Part 1 of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokinetics of \[68Ga\]Ga-DFC413, and in Part 2 compare to \[68Ga\]Ga-NNS309 in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC), colorectal cancer (CRC), and soft tissue sarcoma (STS). In Part 2 of this study (comparison of \[68Ga\]Ga-DFC413 and \[68Ga\]Ga-NNS309), not all indications might be explored.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-11
Trial Details
NCT Number NCT07630961
Lead Sponsor Novartis Pharmaceuticals
Conditions Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer (BC), HR+/HER2- Lobular Breast Cancer (BC), Triple Negative Breast Cancer (TNBC), Colorectal Cancer (CRC), Soft Tissue Sarcoma (STS)
Enrollment 66 participants
Start Date 2026-06-23
Primary Completion 2028-01-16 (estimated)
Study Completion 2028-01-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-28